Plus   Neg

Abbott To Launch NeuroSphere MyPath Digital Health App - Quick Facts

Abbott Laboratories (ABT) said Thursday it will launch NeuroSphere myPath, a digital health app designed to track and report on patient perceived pain relief and general well-being associated with spinal cord stimulation (SCS) or dorsal root ganglion (DRG) therapy.

During the device trial period required before the permanent implant, the app allows patients to record their outcomes on pain and well-being while trialing their neurostimulation therapy.

Abbott expects NeuroSphere myPath will provide relief to the millions of Americans currently living with chronic pain that are eligible for SCS or DRG therapy.

This new digital health app will allow patients to use their Apple mobile device to connect with Abbott support, access educational resources, and track the progress of their trial pain relief journey.

Prior to committing to full implantation of a neuromodulation device, patients will undergo a trial period to test device capabilities and capacity for pain relief.

During the trial, temporary leads are placed and connected to an external generator, allowing patients to experience first-hand the impact of neuromodulation on their chronic pain and related symptoms.

Abbott noted that NeuroSphere myPath fits within the company's broader NeuroSphere Digital Care connected health management platform.

It will be compatible with Abbott's Proclaim XR SCS System for patients living with chronic pain in the trunk and limbs, and Proclaim DRG Neurostimulation System for patients with chronic pain in the lower limbs caused by complex regional pain syndrome or causalgia.

Abbott said the NeuroSphere myPath will be available on the Apple App Store in the coming weeks. It is expected to be available on Android devices in the second quarter of 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Intel Corp. (INTC) Thursday reported a profit and revenues for the first quarter that trumped Wall Street estimates, driven by continued demand for PCs. Moving ahead, the company lifted its full-year outlook. Santa Clara, California-based Intel reported first-quarter profit of $3.36 billion or $0.82... A third of those American adults now refusing to get vaccinated would get vaccinated if they could take a pill instead of getting the vaccine shot, according to a poll conducted by Quadrant Strategies and commissioned by biotechnology company Vaxart, Inc. A pill vaccine is expected to overcome vaccine resistance of millions of Americans. While reporting financial results for the first quarter on Thursday, Biogen Inc. (BIIB) raised its adjusted earnings guidance for the full-year 2021, but maintained revenue outlook. For fiscal 2021, the company raised its adjusted earnings guidance to a range of $17.50 to $19.00 per share from the...
Follow RTT